Argus initiated coverage of Solventum Corporation with a rating of Hold
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/8/2024 | $82.00 | Buy | Stifel |
| 10/7/2024 | $71.00 | Neutral | Piper Sandler |
| 9/26/2024 | Peer Perform | Wolfe Research | |
| 9/5/2024 | Neutral | BTIG Research | |
| 6/24/2024 | Hold | Argus | |
| 5/30/2024 | $54.00 | Sell | Goldman |
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
4 - Solventum Corp (0001964738) (Issuer)
SC 13G/A - Solventum Corp (0001964738) (Subject)
ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi
UPS: -9% | United Parcel Service Q2 2024 Adj EPS $1.79 Misses $1.99 Estimate, Sales $21.820B Miss $22.183B Estimate SOLV: 6.9% | Solventum shares are trading higher following a report suggesting Trian has built a stake in the company. TUSK: 57% | Mammoth Energy Services shares are trading higher after the company announced its subsidiary, Cobra Acquisitions, entered into a release and settlement agreement with the Puerto Rico Electric Power Authority.
Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3%GAAP Earnings Per Share (EPS) of $0.70; adjusted EPS1 of $1.64Generated $169 million in cash from operations; free cash flow1 of $76 millionRaises full-year 2024 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2024. "We have now delivered consecutive quarters of outperformance against our expectations, and based on these results, we are again rai
ST. PAUL, Minn., Oct. 15, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its third quarter 2024 financial results on Thursday, November 7, 2024 after the U.S. financial markets close. The company will also host a conference call that day at 4:30 p.m. Eastern Time to discuss its third quarter financial results and provide an update on its business. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers using the conference ID #6342275. A replay of the w
ST. PAUL, Minn., Oct. 14, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV), formerly 3M Health Care, today pledges to use 100% renewable electricity across its worldwide operations by 2030. This move highlights Solventum's commitment to sustainability and the critical role of the healthcare industry in addressing climate change. It also demonstrates how the company is integrating sustainable practices in its facilities and innovating solutions for customers. Since 2021, Solventum has transitioned ten manufacturing sites across the United States, Canada, Germany, Poland and France to
Stifel initiated coverage of Solventum Corporation with a rating of Buy and set a new price target of $82.00
Piper Sandler initiated coverage of Solventum Corporation with a rating of Neutral and set a new price target of $71.00
Wolfe Research initiated coverage of Solventum Corporation with a rating of Peer Perform
IRANNOTICE - Solventum Corp (0001964738) (Filer)
10-Q - Solventum Corp (0001964738) (Filer)
8-K - Solventum Corp (0001964738) (Filer)
Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3%GAAP Earnings Per Share (EPS) of $0.70; adjusted EPS1 of $1.64Generated $169 million in cash from operations; free cash flow1 of $76 millionRaises full-year 2024 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Nov. 7, 2024 /PRNewswire/ -- Solventum (NYSE: SOLV) today reported financial results for the third quarter ended September 30, 2024. "We have now delivered consecutive quarters of outperformance against our expectations, and based on these results, we are again rai
ST. PAUL, Minn., Oct. 15, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its third quarter 2024 financial results on Thursday, November 7, 2024 after the U.S. financial markets close. The company will also host a conference call that day at 4:30 p.m. Eastern Time to discuss its third quarter financial results and provide an update on its business. The conference call can be accessed via audio webcast at investors.solventum.com or by dialing (800) 715-9871 within the U.S. or +1 (646) 307-1963 for international callers using the conference ID #6342275. A replay of the w
Separation activities and business continuity on trackReported sales increased 0.2% to $2.081 billion; organic sales increased 1.3%GAAP Earnings Per Share (EPS) of $0.51; adjusted EPS1 of $1.56Generated $355 million in cash from operations; free cash flow1 of $297 millionRaises full-year 2024 organic sales growth and adjusted EPS guidanceST. PAUL, Minn., Aug. 8, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results as a stand-alone company for the second quarter ended June 30, 2024. "As we continue to execute a complex transformation, we're encouraged by